Adaptimmune Therapeutics PLC – (ADAP) Expected to Announce Earnings of -$0.03 Per Share

Share on StockTwits

Wall Street analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to post earnings per share of ($0.03) for the current quarter, according to Zacks. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.19) to $0.26. The business is scheduled to issue its next earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.27) to ($0.68). For the next fiscal year, analysts expect that the company will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to the consensus estimate of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%.

Several equities research analysts have recently issued reports on ADAP shares. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 24th. Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, August 2nd. Guggenheim began coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They issued a “buy” rating on the stock. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.33.

Shares of Adaptimmune Therapeutics stock traded down $0.12 on Tuesday, hitting $10.76. 594,791 shares of the company traded hands, compared to its average volume of 468,993. The stock has a market cap of $1.02 billion, a P/E ratio of -13.45 and a beta of 1.07. Adaptimmune Therapeutics has a 52 week low of $6.60 and a 52 week high of $14.63.

In other Adaptimmune Therapeutics news, Director Ali Behbahani purchased 12,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average price of $1.67 per share, for a total transaction of $20,040,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. Insiders own 26.47% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. boosted its stake in Adaptimmune Therapeutics by 18.2% during the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock worth $36,005,000 after buying an additional 467,852 shares during the period. Millennium Management LLC boosted its stake in Adaptimmune Therapeutics by 83.4% during the first quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock worth $16,594,000 after buying an additional 672,046 shares during the period. BlackRock Inc. boosted its stake in Adaptimmune Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock worth $9,062,000 after buying an additional 19,765 shares during the period. Dorsey Wright & Associates purchased a new position in Adaptimmune Therapeutics during the second quarter worth $6,981,000. Finally, JPMorgan Chase & Co. boosted its stake in Adaptimmune Therapeutics by 786.0% during the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after buying an additional 164,704 shares during the period. 59.32% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: Earnings Reports

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply